Clinical Trials Browser

Phase 2 × INDUSTRY × erdafitinib × Clear all

NCT02365597 2026-06-05

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

Phase 2 Active not recruiting

239 enrolled 32 charts 1 FDA

Urothelial Cancer

NCT04083976 2026-05-04

RAGNAR

Phase 2 Completed

316 enrolled 15 charts

Other solid neoplasm

Advanced Solid Tumor

NCT04172675 2026-02-24

A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

Phase 2 Completed

107 enrolled 17 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT02699606 2025-04-27

A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma

Phase 2 Completed

GastrointestinalThoracic

Acrocephalosyndactylia, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Neoplasms, Cholangiocarcinoma